MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes

被引:2
作者
Guo, Chao [1 ]
Gao, Ya-yue [1 ]
Ju, Qian-qian [1 ]
Wang, Min [1 ]
Zhang, Chun-xia [1 ]
Gong, Ming [1 ]
Li, Zhen-ling [1 ]
机构
[1] China Japan Friendship Hosp, Dept Hematol, Yinghua East St, Beijing, Peoples R China
关键词
Polycythemia vera; WGCNA; MAPK14; Expression; TYROSINE KINASE JAK2; ESSENTIAL THROMBOCYTHEMIA; TNF-ALPHA; MUTATION; NEOPLASMS; CELLS;
D O I
10.1186/s12967-021-02913-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundThe transcriptomic signature has not been fully elucidated in PV, as well as mRNA markers for clinical variables (thrombosis, leukemic transformation, survival, etc.). We attempted to reveal and validate crucial co-expression modules and marker mRNAs correlating with polycythemia vera (PV) by weighted gene co-expression network analysis (WGCNA).Material and methodsThe GSE57793/26014/61629 datasets were downloaded from Gene Expression Omnibus (GEO) database and integrated into one fused dataset. By R software and 'WGCNA' package, the PV-specific co-expression module was identified, the pathway enrichment profile of which was obtained by over-representation analysis (ORA). Protein-protein interaction (PPI) network and hub gene analysis identified MAPK14 as our target gene. Then the distribution of MAPK14 expression in different disease/mutation types, were depicted based on external independent datasets. Genome-scale correlation analysis revealed the association of MAPK14 and JAK/STAT family genes. Then gene set enrichment analysis (GSEA) was performed to detect the activated and suppressed pathways associating with MAPK14 expression. Moreover, GSE47018 dataset was utilized to compare clinical variables (thrombosis, leukemic transformation, survival, etc.) between MAPK14-high and MAPK14-low groups.ResultsAn integrated dataset including 177 samples (83 PV, 35 ET, 17 PMF and 42 normal donors) were inputted into WGCNA. The 'tan' module was identified as the PV-specific module (R-2=0.56, p=8e-16), the genes of which were dominantly enriched in pro-inflammatory pathways (Toll-like receptor (TLR)/TNF signaling, etc.). MAPK14 is identified as the top hub gene in PV-related PPI network with the highest betweenness. External datasets validated that the MAPK14 expression was significantly higher in PV than that of essential thrombocytosis (ET)/primary myelofibrosis (PMF) patients and normal donors. JAK2 homozygous mutation carriers have higher level of MAPK14 than that of other mutation types. The expression of JAK/STAT family genes significantly correlated with MAPK14, which also contributed to the activation of oxidated phosphorylation, interferon-alpha (IFN alpha) response and PI3K-Akt-mTOR signaling, etc. Moreover, MAPK14-high group have more adverse clinical outcomes (splenectomy, thrombosis, disease aggressiveness) and inferior survival than MAPK14-low group.ConclusionMAPK14 over-expression was identified as a transcriptomic feature of PV, which was also related to inferior clinical outcomes. The results provided novel insights for biomarkers and therapeutic targets for PV.
引用
收藏
页数:13
相关论文
共 39 条
[1]   Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms [J].
Allain-Maillet, Sophie ;
Bosseboeuf, Adrien ;
Mennesson, Nicolas ;
Bostoen, Megane ;
Dufeu, Laura ;
Choi, Eun Ho ;
Cleyrat, Cedric ;
Mansier, Olivier ;
Lippert, Eric ;
Le Bris, Yannick ;
Gombert, Jean-Marc ;
Girodon, Francois ;
Pettazzoni, Magali ;
Bigot-Corbel, Edith ;
Hermouet, Sylvie .
CANCERS, 2020, 12 (09) :1-24
[2]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[3]   Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms [J].
Baumeister, Julian ;
Chatain, Nicolas ;
Hubrich, Annika ;
Maie, Tiago ;
Costa, Ivan G. ;
Denecke, Bernd ;
Han, Lijuan ;
Kuestermann, Caroline ;
Sontag, Stephanie ;
Sere, Kristin ;
Strathmann, Klaus ;
Zenke, Martin ;
Schuppert, Andreas ;
Bruemmendorf, Tim H. ;
Kranc, Kamil R. ;
Koschmieder, Steffen ;
Gezer, Deniz .
LEUKEMIA, 2020, 34 (04) :1062-1074
[4]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[5]   Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].
Bettelli, E ;
Carrier, YJ ;
Gao, WD ;
Korn, T ;
Strom, TB ;
Oukka, M ;
Weiner, HL ;
Kuchroo, VK .
NATURE, 2006, 441 (7090) :235-238
[6]   mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms [J].
Bogani, Costanza ;
Bartalucci, Niccolo ;
Martinelli, Serena ;
Tozzi, Lorenzo ;
Guglielmelli, Paola ;
Bosi, Alberto ;
Vannucchi, Alessandro M. .
PLOS ONE, 2013, 8 (01)
[7]   Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells [J].
Fiskus, Warren ;
Verstovsek, Srdan ;
Manshouri, Taghi ;
Smith, Jacqueline E. ;
Peth, Karissa ;
Abhyankar, Sunil ;
McGuirk, Joseph ;
Bhalla, Kapil N. .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (05) :577-588
[8]   TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms [J].
Fleischman, Angela G. ;
Aichberger, Karl J. ;
Luty, Samuel B. ;
Bumm, Thomas G. ;
Petersen, Curtis L. ;
Doratotaj, Shirin ;
Vasudevan, Kavin B. ;
LaTocha, Dorian H. ;
Yang, Fei ;
Press, Richard D. ;
Loriaux, Marc M. ;
Pahl, Heike L. ;
Silver, Richard T. ;
Agarwal, Anupriya ;
O'Hare, Thomas ;
Druker, Brian J. ;
Bagby, Grover C. ;
Deininger, Michael W. .
BLOOD, 2011, 118 (24) :6392-6398
[9]   A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms [J].
Guijarro-Hernandez, Ana ;
Vizmanos, Jose Luis .
CANCERS, 2021, 13 (05) :1-24
[10]   Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression [J].
Hasselbalch, Hans Carl ;
Thomassen, Mads ;
Riley, Caroline Hasselbalch ;
Kjaer, Lasse ;
Larsen, Thomas Stauffer ;
Jensen, Morten K. ;
Bjerrum, Ole Weis ;
Kruse, Torben A. ;
Skov, Vibe .
PLOS ONE, 2014, 9 (11)